Brian C. Grieb, MD, PhD

Brian C. Grieb, MD, PhD, discusses unmet needs for patients with colorectal cancer, including the identification of novel pan-CRC biomarkers for drug development.

Brian C. Grieb, MD, PhD, emphasizes the importance of investigating agents that target the MYC oncogene, as well as supportive cofactors, in colorectal cancer and other tumor types.

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors.